Results Insulin Treatment of BBDP Rats Results (cont) Optimization of Insulin Treatment for Spontaneous Type 1 Diabetes (T1D) in BBDP/Wor Rats Barak Yahalom,

Slides:



Advertisements
Similar presentations
Biomedical Research Models, Inc., Worcester, MA
Advertisements

In the name of GOD In the name of GOD.
Medications Insulin. Without Insulin With Treatment of Insulin.
1 Type 1 Diabetes Mellitus Treatment. 2 Goals of T1DM Management Utilize intensive therapy aimed at near-normal BG and A1C levels Prevent diabetic ketoacidosis.
Amelioration of Hyperalgesia by Gliclazide and Some Antioxidants in STZ diabetic Animals Hekma A. Abd El-Latif * Hekma A. Abd El-Latif * Abstract Neuropathy.
Canadian Diabetes Assocaition Clinical Practice Guidelines Pharmacotherapy in Type 1 Diabetes Chapter 12 Angela McGibbon, Cindy Richardson, Cheri Hernandez,
New Insulin Glargine 300 Units∙mL2-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine.
Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.
Diabetes Update: Living Life after Lente
Unique Drug Combination for Reversal of Type 1 Diabetes Sarah A. Tersey, Jeffrey D. Carter, Elizabeth Z. Kropf, Lawrence Rosenberg*, Jerry L. Nadler Department.
Insulin therapy.
GENE THERAPY FOR DIABETES Lindsey Rowbotham Period 7.
INSULIN THERAPY IN TYPE 1 DIABETES
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus Matthew Faiman.
L.M. Fisk, A.J. Le Compte, G.M. Shaw, S. Penning, T. Desaive, J.G. Chase Pilot Trial of STAR in Medical ICU INTRODUCTION Background: Accurate glycemic.
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Titrating Insulin to Glycemic Target Judy Bowen, MD CIM Rotation September, 2006.
Inpatient Glycemic Management
Journal Club 2009 年 1 月 29 日(木) 8 : 20 ~ 8 : 50 B 棟 8 階カンファレンスルーム 薬剤部 TTSP 石井 英俊.
Acknowledgement We would like to thank ORSP for funding. Acknowledgement We would like to thank ORSP for funding. Introduction Mice are nocturnal animals.
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Toujeo® and it’s Place in Therapy
POSTER TEMPLATE BY: Long Acting Insulin for the Treatment of Diabetes Mellitus Kim Tran, Eric Tang, Randa Rifai, Udo Oji Touro.
Patient-directed titration to achieve glycaemic goals in type 2 diabetes using once-daily basal insulin: results of the TITRATE randomized controlled trial.
Dr Stanley Ngare.  Pharmacology of Types of insulin available  Various routes of delivery & factors that affect absorption  Patient and provider barriers.
Insulin Glargine (Lantus) Lantus is a long-acting insulin that should be injected below the skin once daily as directed by your doctor. Take Lantus the.
Tresiba- insulin degludec
Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride Kann P, Regulski M, Medding J, Ligthelm R A study in people with type.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Diabetes Mellitus Part 2 Kathy Martin DNP, RN, CNE.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
Quality of Life Matters NOT TOO HIGH… NOT TOO LOW… A PLAN FOR OPTIMIZING DIABETES MANAGEMENT IN NURSING HOMES 5. Insulin: Part 1.
Representative insulin regimens for the treatment of diabetes
Jill Little Diabetes Specialist Nurse
Key publication slides
Figure 3. The relationship between testosterone dose and mean serum total testosterone. Data are shown as mean serum total testosterone among measurements.
Key publication slides
Supplemental Digital Content 2
Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs  Maria Luisa Jaén, Laia Vilà, Ivet Elias,
Copyright © 2004 American Medical Association. All rights reserved.
Insulin Detemir versus Glyburide in Women with
From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.
Jill Little Diabetes Specialist Nurse
Insulin Safety know your insulins! There are many! Humalog® Mix25 Humalog® Mix50 Humulin® I Humulin® M3 Humulin® S Humalog® U-100 Humalog® U-200.
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
Systemic Administration of Multipotent Mesenchymal Stromal Cells Reverts Hyperglycemia and Prevents Nephropathy in Type 1 Diabetic Mice  Fernando E. Ezquer,
Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.
Faster-Acting Insulins
Volume 16, Issue 8, Pages (August 2008)
The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Novel Approaches to T1D Management
What Does It Take to Be a Long-Acting Replacement Therapy in Hemophilia A?
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Dual SGLT1/SGLT2 Inhibition in T1D
Phase 2 Treatment Naïve Elbasvir-Grazoprevir + Sofosbuvir in Treatment-Naïve HCV Genotype 1 or 3 C-SWIFT Poordad F, et al. EASL 2015; Abstract O006.
Long-Term Efficacy and Safety of Insulin and Glucokinase Gene Therapy for Diabetes: 8-Year Follow-Up in Dogs  Maria Luisa Jaén, Laia Vilà, Ivet Elias,
Managing Hypoglycemia & Hyperglycemia
Volume 16, Issue 8, Pages (August 2008)
Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene
Volume 23, Issue 3, Pages (March 2016)
Volume 57, Issue 5, Pages (May 2000)
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Body weight, blood glucose, and iron status in STZ-induced type 1 diabetic rats with or without insulin therapy. Body weight, blood glucose, and iron status.
Appearance of insulin in plasma and CSF at different times after the administration of subcutaneous DET and GLAR in mice and the effect of chronic DET.
GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.
Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.
Molecular Therapy - Nucleic Acids
Insulin in Type 2 Diabetes
Presentation transcript:

Results Insulin Treatment of BBDP Rats Results (cont) Optimization of Insulin Treatment for Spontaneous Type 1 Diabetes (T1D) in BBDP/Wor Rats Barak Yahalom, Shane K. Duclos, Dennis L. Guberski, Christian W. Grant and Joan F. Flanagan Biomedical Research Models, Inc., Worcester, MA Introduction New long acting types of insulin capable of maintaining blood glucose levels within a near- normal range are in great demand for use in rodent models of T1D. However, standardized protocols (SP) for maintaining normoglycemia in preclinical diabetic rodent models are lacking. Therefore, we evaluated the efficacy of new long acting insulins for maintaining glycemic levels in our spontaneous T1D BBDR/Wor rat colony. Factors considered in the development of this SP included both the type of insulin and treatment regimen relative to fed state. Cohorts of BBDP/Wor rats that exhibited chronic diabetes were used in these studies. Several types of insulins: protamine zinc (PZI; 90% beef, 10% pork), Lantus (glargine, rDNA), Levemir (detemir, rDNA) or ProZinc (protamine zinc, recombinant human) were evaluated by a single subcutaneous injection to maintain normoglycemia within a 24 hour period. Next, the optimum timing of insulin administration for glycemic control was compared when therapies were administered during the non- fed or fed state by measuring blood glucose levels every hours over a 24 hour period. Our data show that the once daily injection of PZI targeted to 0.9U/100g body weight was superior for maintaining daily glycemic control in diabetic rats to both Lantus and Levemir when administered at the same dose. Interestingly, a comparable dose of ProZinc exhibited enhanced duration of normoglycemia compared to PZI. Moreover, similar to human treatment regimens, insulin administration just prior to fed-state with either PZI or ProZinc provided safer and longer daily glycemic control compared to insulin treatment at the non-fed state. In summary, once daily, subcutaneously injection of either Prozinc or PZI insulins, administered just prior to the fed-state, are effective at maintaining daily glycemic levels in spontaneously diabetic BBDP/Wor rats. This knowledge will allow for more accurate mimicking of that expected in human patients in our preclinical efficacy trials. Methods Animal Models BBDP/Wor Rats Chronic diabetic male rats Duration of days Diagnosis of Diabetes Rats were screened 3x/week for glycosuria Animals with a positive glycosuria and serum glucose level of >250mg/dL were considered diabetic Insulin Treatment Protocols Insulins were injected subcutaneously (sc) at 0.9U/100g body weight Blood glucose levels were measured by handheld glucometer over a 24-hour period post insulin administration Factors considered: Type of insulin: PZI ® (protamine zinc Insulin;90% beef, 10% pork) Lantus ® (glargine, rDNA), Levemir ® (detemir, rDNA) ProZinc ® (protamine zinc, recombinant human) Timing of dose relative to fed state: Two hours before fed-state Six hours before fed-state Figure 1: Average Serum Glucose Among Diabetic Male BBDP/WOR Rats Treated with different insulin regimens. A) ProZinc Vs Levemir Insulin at 6 hours before fed state. B) PZI, Lantus and ProZinc at 2 hours before fed state Figure 1: (A) Groups of 10 diabetic male BBDP rats were treated with either a single dose of ProZinc (green squares) or Levemir (black triangles) at 6 hours before fed state. (B) A group of 8-10 diabetic male BBDP rats were treated with a single dose of PZI (red), Lantus (dark blue) or Prozinc(green) at 2 hours before fed state. Serum glucose levels were measured every 2 hours, except for (A) 1 time point was 10 hours apart. Mean +/- SEM are depicted. A single injection of Levemir at 0.9U/100g BW at 6 hours before fed state did not provide effective glycemic control. A single injection of Lantus at 0.9U/100g BW or 1.1U/100g BW (data not shown) at 2 hours before fed state did not provide effective glycemic control. A single injection of ProZinc was enhanced compared to PZI insulin to maintain normoglycemia control over 24 hours. PZI or Prozinc insulin were more effective when administered before fed state. Acknowledgements This work was funded by BRM, and performed by the Springfield facility technical staff Insulin administration just prior to fed-state with either PZI or ProZinc provided safer and longer daily glycemic control in BBDP/Wor rats compared to an early treatment at the non-fed state. Conclusion